Document is current
Any future updates will be listed below
-
Authors
Wilk, Aaron J.
Marceau, Joshua O.
Kazer, Samuel W.
Fleming, Ira
Miao, Vincent N.
Galvez-Reyes, Jennyfer
Kimata, Jason T.
Shalek, Alex K.
Holmes, Susan
Overbaugh, Julie
Blish, Catherine A. https://orcid.org/0000-0001-6946-7627
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32 GM007365-44)
National Institute on Drug Abuse (DP1 DA04508902, 1DP1DA053731)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD103571)
National Cancer Institute (1U54CA217377, U01 28020510, 1U2CCA23319501)
Bill and Melinda Gates Foundation (INV-027498, OPP1202327)
- License Information
-
More Information
Article History
Received: 17 April 2023
Accepted: 19 January 2024
First Online: 5 February 2024
Declarations
:
: Samples from pig-tailed macaques used in this study were collected as part of a study by Kimata et al. [], published in 1999. No additional animal work was performed in this study. Our use of these samples was reviewed and approved by Stanford University’s Animal Care and Use Committee as APLAC-33350. This research conforms to the principles of the Helsinki Declaration.
: Not applicable.
: A. K. S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Ochre Bio, Third Rock Ventures, Hovione, Relation Therapeutics, FL82, FL86, Bio-Rad Laboratories, Empress Therapeutics, IntrECate Biotherapeutics, Senda Biosciences, and Dahlia Biosciences unrelated to this work. C. A. B. reports compensation for consulting and/or SAB membership from Catamaran Bio, DeepCell Inc., Immunebridge, and Revelation Biosciences. J. O. reports SAB membership for Aerium Therapeutics. V. N. M. reports compensation from MPM Capital unrelated to this work. S. W. K. reports compensation for consulting from Radera Biotherapeutics and Monopteros Therapeutics. All other authors declare that they have no competing interests.
